Pyxis Oncology reported updated results from its ongoing global Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma. As of October 14, 2026, among 33 efficacy evaluable patients, the confirmed objective response rate was 39% and median progression-free survival was 6.7 months. The company plans to advance MICVO into a global Phase 3 trial, planned to initiate in mid-2027.
PYXS · Pyxis Oncology, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements were issued.”View the 10-Q filed Aug 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 41%
- Last earnings
- Nov 19, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Oct 2021 to Nov 2026
Up next
Latest documents
Pyxis Oncology, Inc. stockholders approved increasing authorized common shares from 190,000,000 to 380,000,000, and the amendment became effective on November 13, 2026.
Pixis plans a 500-patient, one-to-one randomized pivotal trial in second-line head and neck cancer, with response rate and overall survival as primary endpoints and first patient dosing planned for the middle part of 2027.
Pyxis Oncology reported MICVO’s 36% confirmed ORR and 94% DCR in 2L+ R/M HNSCC, plans the global pivotal Phase 3 HeadlinerSM trial for mid-2027, and expects resources to fund operations into the first half of 2028.
Pyxis Oncology reported a 36% confirmed objective response rate (12/33) for MICVO and plans to initiate the global Phase 3 HeadlinerSM trial in mid-2027. Cash plus net offering proceeds is expected to fund operations into the first half of 2028.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash and cash equivalents, including restricted cash, and short-term investments | $57M | As of September 30, 2026 | — |
| Confirmed objective response rate | 36% | Phase 1 monotherapy data cutoff of August 18, 2026 | — |
| Disease control rate | 94% | Phase 1 monotherapy data cutoff of August 18, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PYXS
this stock
Pyxis Oncology, Inc.
|
$216.49M | +57.4% | -14.2% | — | 3.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 19, 2026
- This year
- 26
Pyxis Oncology reported updated results from its ongoing global Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma. As of October 14, 2026, among 33 efficacy evaluable patients, the confirmed objective response rate was 39% and median progression-free survival was 6.7 months. The company plans to advance MICVO into a global Phase 3 trial, planned to initiate in mid-2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PYXS | +14.6% | +7.7% | +5.9% | +0.0% | +57.4% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +23.1% | +17.0% | +15.0% | +8.7% | +56.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.